Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Decreasing time to antiretroviral therapy initiation after HIV diagnosis in a clinic-based observational cohort study in four African countries.

Esber AL, Coakley P, Ake JA, Bahemana E, Adamu Y, Kiweewa F, Maswai J, Owuoth J, Robb ML, Polyak CS, Crowell TA; AFRICOS Study Group.

J Int AIDS Soc. 2020 Feb;23(2):e25446. doi: 10.1002/jia2.25446.

PMID:
32064776
2.

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.

Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Dawson P, Dhitavat J, Phonrat B, Akapirat S, Karasavvas N, Wieczorek L, Polonis V, Eller MA, Pegu P, Kim D, Schuetz A, Jongrakthaitae S, Zhou Y, Sinangil F, Phogat S, Diazgranados CA, Tartaglia J, Heger E, Smith K, Michael NL, Excler JL, Robb ML, Kim JH, O'Connell RJ, Vasan S; RV306 study group.

Lancet HIV. 2020 Feb 6. pii: S2352-3018(19)30406-0. doi: 10.1016/S2352-3018(19)30406-0. [Epub ahead of print]

PMID:
32035516
3.

Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand.

Rolland M, Tovanabutra S, Dearlove B, Li Y, Owen CL, Lewitus E, Sanders-Buell E, Bose M, O'Sullivan A, Rossenkhan R, Labuschagne JPL, Edlefsen PT, Reeves DB, Kijak G, Miller S, Poltavee K, Lee J, Bonar L, Harbolick E, Ahani B, Pham P, Kibuuka H, Maganga L, Nitayaphan S, Sawe FK, Eller LA, Gramzinski R, Kim JH, Michael NL, Robb ML; RV217 Study Team.

PLoS Pathog. 2020 Feb 6;16(2):e1008179. doi: 10.1371/journal.ppat.1008179. eCollection 2020 Feb.

4.

Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption.

Mitchell JL, Takata H, Muir R, Colby DJ, Kroon E, Crowell TA, Sacdalan C, Pinyakorn S, Pattamaswin S, Benjapornpong K, Trichavaroj R, Tressler RL, Fox L, Polonis VR, Bolton DL, Maldarelli F, Lewin SR, Haddad EK, Phanuphak P, Robb ML, Michael NL, de Souza M, Phanuphak N, Ananworanich J, Trautmann L.

J Clin Invest. 2020 Feb 4. pii: 130597. doi: 10.1172/JCI130597. [Epub ahead of print]

5.

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.

Dussupt V, Sankhala RS, Gromowski GD, Donofrio G, De La Barrera RA, Larocca RA, Zaky W, Mendez-Rivera L, Choe M, Davidson E, McCracken MK, Brien JD, Abbink P, Bai H, Bryan AL, Bias CH, Berry IM, Botero N, Cook T, Doria-Rose NA, Escuer AGI, Frimpong JA, Geretz A, Hernandez M, Hollidge BS, Jian N, Kabra K, Leggat DJ, Liu J, Pinto AK, Rutvisuttinunt W, Setliff I, Tran U, Townsley S, Doranz BJ, Rolland M, McDermott AB, Georgiev IS, Thomas R, Robb ML, Eckels KH, Barranco E, Koren M, Smith DR, Jarman RG, George SL, Stephenson KE, Barouch DH, Modjarrad K, Michael NL, Joyce MG, Krebs SJ.

Nat Med. 2020 Feb;26(2):228-235. doi: 10.1038/s41591-019-0746-2. Epub 2020 Feb 3.

PMID:
32015557
6.

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.

Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L, Dintwe O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E, Michael NL, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, De Rosa SC, Corey L, Gray GE, Seaton KE, Yates NL, McElrath MJ, Frahm N, Tomaras GD, Gilbert PB.

PLoS One. 2020 Jan 30;15(1):e0226803. doi: 10.1371/journal.pone.0226803. eCollection 2020.

7.

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.

Easterhoff D, Pollara J, Luo K, Janus B, Gohain N, Williams LD, Tay MZ, Monroe A, Peachman K, Choe M, Min S, Lusso P, Zhang P, Go EP, Desaire H, Bonsignori M, Hwang KK, Beck C, Kakalis M, O'Connell RJ, Vasan S, Kim JH, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Arthos J, Rao M, Joyce MG, Ofek G, Ferrari G, Haynes BF.

JCI Insight. 2020 Jan 30;5(2). pii: 131437. doi: 10.1172/jci.insight.131437.

8.

Resting-state neural signatures of depressive symptoms in acute HIV.

Philippi CL, Reyna L, Nedderman L, Chan P, Samboju V, Chang K, Phanuphak N, Ratnaratorn N, Hellmuth J, Benjapornpong K, Dumrongpisutikul N, Pothisri M, Robb ML, Ananworanich J, Spudich S, Valcour V, Paul R; SEARCH 010/RV254 and RV304/SEARCH 013 study teams.

J Neurovirol. 2020 Jan 27. doi: 10.1007/s13365-020-00826-3. [Epub ahead of print]

PMID:
31989446
9.

Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection.

Peluso MJ, Colby DJ, Pinyakorn S, Ubolyam S, Intasan J, Trichavaroj R, Chomchey N, Prueksakaew P, Slike BM, Krebs SJ, Jian N, Robb ML, Phanuphak P, Phanuphak N, Spudich S, Ananworanich J, Kroon E; SEARCH010/RV254 Study Group.

J Int AIDS Soc. 2020 Jan;23(1):e25444. doi: 10.1002/jia2.25444.

10.

Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection.

Lal KG, Kim D, Costanzo MC, Creegan M, Leeansyah E, Dias J, Paquin-Proulx D, Eller LA, Schuetz A, Phuang-Ngern Y, Krebs SJ, Slike BM, Kibuuka H, Maganga L, Nitayaphan S, Kosgei J, Sacdalan C, Ananworanich J, Bolton DL, Michael NL, Shacklett BL, Robb ML, Eller MA, Sandberg JK.

Nat Commun. 2020 Jan 14;11(1):272. doi: 10.1038/s41467-019-13975-9.

11.

Anorectal and Urogenital Mycoplasma genitalium in Nigerian Men Who Have Sex With Men and Transgender Women: Prevalence, Incidence, and Association With HIV.

Crowell TA, Lawlor J, Lombardi K, Nowak RG, Hardick J, Odeyemi S, Kokogho A, Malia J, Stewart C, Robb ML, Baral SD, Adebajo S, Charurat ME, Ake JA, Peel SA, Gaydos CA; TRUST/RV368 Study Group.

Sex Transm Dis. 2020 Mar;47(3):202-206. doi: 10.1097/OLQ.0000000000001105.

PMID:
31880740
12.

The US Military HIV Natural History Study: Informing Military HIV Care and Policy for Over 30 Years.

Agan BK, Ganesan A, Byrne M, Deiss R, Schofield C, Maves RC, Okulicz J, Chu X, O'Bryan T, Lalani T, Kronmann K, Ferguson T, Robb ML, Whitman TJ, Burgess TH, Michael N, Tramont E; Infectious Disease Clinical Research Program HIV Working Group.

Mil Med. 2019 Nov 1;184(Supplement_2):6-17. doi: 10.1093/milmed/usy430.

PMID:
31778201
13.

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.

Easterhoff D, Pollara J, Luo K, Tolbert WD, Young B, Mielke D, Jha S, O'Connell RJ, Vasan S, Kim J, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Pazgier M, Haynes BF, Ferrari G.

J Virol. 2020 Jan 31;94(4). pii: e01120-19. doi: 10.1128/JVI.01120-19. Print 2020 Jan 31.

14.

Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART.

Eller MA, Hong T, Creegan M, Nau ME, Sanders-Buell E, Slike BM, Krebs SJ, Ratto-Kim S, McElrath MJ, Katabira ET, Bolton DL, Michael NL, Robb ML, Tovanabutra S, Baeten JM, Sandberg JK.

AIDS. 2020 Feb 1;34(2):197-202. doi: 10.1097/QAD.0000000000002432.

PMID:
31764072
15.

Chikungunya and O'nyong-nyong Viruses in Uganda: Implications for Diagnostics.

Clements TL, Rossi CA, Irish AK, Kibuuka H, Eller LA, Robb ML, Kataaha P, Michael NL, Hensley LE, Schoepp RJ.

Open Forum Infect Dis. 2019 Jan 3;6(3):ofz001. doi: 10.1093/ofid/ofz001. eCollection 2019 Mar.

16.

Genetic clustering analysis for HIV infection among MSM in Nigeria: implications for intervention.

Li Y, Liu H, Ramadhani HO, Ndembi N, Crowell TA, Kijak G, Robb ML, Ake JA, Kokogho A, Nowak RG, Gaydos C, Baral SD, Volz E, Tovanabutra S, Charurat M; TRUST/RV368 Study Group.

AIDS. 2020 Feb 1;34(2):227-236. doi: 10.1097/QAD.0000000000002409.

PMID:
31634185
17.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, Tomaras GD, Frahm N, Montefiori DC, Ferrari G, Ding S, Lee C, Robb ML, Esteban M, Wagner R, Bart PA, Rettby N, McElrath MJ, Gilbert PB, Kublin JG, Corey L; NIAID HIV Vaccine Trials Network.

Lancet HIV. 2019 Nov;6(11):e737-e749. doi: 10.1016/S2352-3018(19)30262-0. Epub 2019 Oct 7. Erratum in: Lancet HIV. 2020 Jan 9;:.

18.

Viral Blips after Treatment Initiation during Acute HIV Infection.

Crowell TA, Pinyakorn S, Sacdalan C, Kroon E, Colby DJ, Puttamaswin S, Ubolyam S, Trichavaroj R, Butterworth O, Turk E, McCullough C, Chomont N, de Souza M, Robb ML, Phanuphak N, Ananworanich J; RV254/SEARCH010 Study Group.

Clin Infect Dis. 2019 Sep 24. pii: ciz936. doi: 10.1093/cid/ciz936. [Epub ahead of print]

PMID:
31550044
19.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.

PMID:
31534016
20.

HIV prevalence and risk behavior among male and female adults screened for enrolment into a vaccine preparedness study in Maputo, Mozambique.

Macicame I, Bhatt N, Matavele Chissumba R, Eller LA, Viegas E, Araújo K, Nwoga C, Li Q, Milazzo M, Hills NK, Lindan C, Michael NL, Robb ML, Jani I, Polyak CS.

PLoS One. 2019 Sep 17;14(9):e0221682. doi: 10.1371/journal.pone.0221682. eCollection 2019.

21.

Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R- Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity.

Naluyima P, Lal KG, Costanzo MC, Kijak GH, Gonzalez VD, Blom K, Eller LA, Creegan M, Hong T, Kim D, Quinn TC, Björkström NK, Ljunggren HG, Serwadda D, Katabira ET, Sewankambo NK, Gray RH, Baeten JM, Michael NL, Wabwire-Mangen F, Robb ML, Bolton DL, Sandberg JK, Eller MA.

J Immunol. 2019 Oct 15;203(8):2210-2221. doi: 10.4049/jimmunol.1900422. Epub 2019 Sep 13.

22.

A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials.

Ehrenberg PK, Shangguan S, Issac B, Alter G, Geretz A, Izumi T, Bryant C, Eller MA, Wegmann F, Apps R, Creegan M, Bolton DL, Sekaly RP, Robb ML, Gramzinski RA, Pau MG, Schuitemaker H, Barouch DH, Michael NL, Thomas R.

Sci Transl Med. 2019 Aug 28;11(507). pii: eaaw4236. doi: 10.1126/scitranslmed.aaw4236.

PMID:
31462510
23.

Recipient Comorbidity and Survival Outcomes after Kidney Transplantation: a UK-wide Prospective Cohort Study.

Wu DA, Robb ML, Forsythe JLR, Bradley C, Cairns J, Draper H, Dudley C, Johnson RJ, Metcalfe W, Ravanan R, Roderick P, Tomson CRV, Watson CJE, Bradley JA, Oniscu GC.

Transplantation. 2019 Aug 19. doi: 10.1097/TP.0000000000002931. [Epub ahead of print]

PMID:
31449188
24.

Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection.

Tovanabutra S, Sirijatuphat R, Pham PT, Bonar L, Harbolick EA, Bose M, Song H, Chang D, Oropeza C, O'Sullivan AM, Balinang J, Kroon E, Colby DJ, Sacdalan C, Hellmuth J, Chan P, Prueksakaew P, Pinyakorn S, Jagodzinski LL, Sutthichom D, Pattamaswin S, de Souza M, Gramzinski RA, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J, Valcour V, Kijak GH, Sanders-Buell E, Spudich S; MHRP Viral Sequencing Core; RV254/SEARCH 010 Study Team.

Cells. 2019 Aug 15;8(8). pii: E902. doi: 10.3390/cells8080902.

25.

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN.

Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24.

PMID:
31351922
26.

Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.

Niu Q, Liu Z, Alamer E, Fan X, Chen H, Endsley J, Gelman BB, Tian B, Kim JH, Michael NL, Robb ML, Ananworanich J, Zhou J, Hu H.

J Clin Invest. 2019 Jul 22;129(8):3361-3373. doi: 10.1172/JCI120633. eCollection 2019 Jul 22.

27.

Switch to dolutegravir is well tolerated in Thais with HIV infection.

Goh OQ, Colby DJ, Pinyakorn S, Sacdalan C, Kroon E, Chan P, Chomchey N, Kanaprach R, Prueksakaew P, Suttichom D, Trichavaroj R, Spudich S, Robb ML, Phanuphak P, Phanuphak N, Ananworanich J; RV254/SEARCH 010 Study Group.

J Int AIDS Soc. 2019 Jul;22(7):e25324. doi: 10.1002/jia2.25324.

28.

Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment.

Rossenkhan R, Rolland M, Labuschagne JPL, Ferreira RC, Magaret CA, Carpp LN, Matsen Iv FA, Huang Y, Rudnicki EE, Zhang Y, Ndabambi N, Logan M, Holzman T, Abrahams MR, Anthony C, Tovanabutra S, Warth C, Botha G, Matten D, Nitayaphan S, Kibuuka H, Sawe FK, Chopera D, Eller LA, Travers S, Robb ML, Williamson C, Gilbert PB, Edlefsen PT.

Viruses. 2019 Jul 3;11(7). pii: E607. doi: 10.3390/v11070607.

29.

Effect of HIV infection and antiretroviral therapy on immune cellular functions.

Korencak M, Byrne M, Richter E, Schultz BT, Juszczak P, Ake JA, Ganesan A, Okulicz JF, Robb ML, de Los Reyes B, Winning S, Fandrey J, Burgess TH, Esser S, Michael NL, Agan BK, Streeck H.

JCI Insight. 2019 Jun 20;4(12). pii: 126675. doi: 10.1172/jci.insight.126675. eCollection 2019 Jun 20.

30.

Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.

Manak MM, Jagodzinski LL, Shutt A, Malia JA, Leos M, Ouellette J, Akapirat S, Colby DL, Phanuphak N, Eller LA, Robb ML, de Souza M, Ananworanich J, Peel SA; RV254/SEARCH010 and the RV217 Study Teams.

J Clin Microbiol. 2019 Sep 24;57(10). pii: e00757-19. doi: 10.1128/JCM.00757-19. Print 2019 Oct.

PMID:
31217270
31.

Correction: Trinh, H.V., et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365.

Trinh HV, Gohain N, Pham PT, Hamlin C, Song H, Sanders-Buell E, Bose M, Eller LA, Jain S, Uritskiy G, Rao VB, Tovanabutra S, Michael NL, Robb ML, Joyce MG, Rao M.

Cells. 2019 Jun 6;8(6). pii: E554. doi: 10.3390/cells8060554.

32.

The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes.

Bai H, Li Y, Michael NL, Robb ML, Rolland M.

PLoS Comput Biol. 2019 Jun 6;15(6):e1007056. doi: 10.1371/journal.pcbi.1007056. eCollection 2019 Jun.

33.

HIV-1 genetic diversity and demographic characteristics in Bulgaria.

Billings E, Heipertz RA, Varleva T, Sanders-Buell E, O'Sullivan AM, Bose M, Howell S, Kijak GH, Taskov H, Elenkov I, Nenova M, Popivanova N, Valenzuela AB, Myles O, Bautista CT, Robb ML, Michael NL, Kim JH, Scott PT, Tovanabutra S, Ake JA.

PLoS One. 2019 May 28;14(5):e0217063. doi: 10.1371/journal.pone.0217063. eCollection 2019.

34.

New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With Men.

Billings E, Kijak GH, Sanders-Buell E, Ndembi N, OʼSullivan AM, Adebajo S, Kokogho A, Milazzo M, Lombardi K, Baral S, Nowak R, Ramadhani H, Gramzinski R, Robb ML, Michael NL, Charurat ME, Ake J, Crowell TA, Tovanabutra S; MHRP Viral Sequencing Core and the TRUST/RV368 Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):578-584. doi: 10.1097/QAI.0000000000002076.

PMID:
31107298
35.

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.

Nadai Y, Held K, Joseph S, Ahmed MIM, Hoffmann VS, Peterhoff D, Missanga M, Bauer A, Joachim A, Reimer U, Zerweck J, McCormack S, Cope AV, Tatoud R, Shattock RJ, Robb ML, Sandstroem EG, Hoelscher M, Maboko L, Bakari M, Kroidl A, Wagner R, Weber J, Pollakis G, Geldmacher C.

Front Immunol. 2019 Apr 24;10:717. doi: 10.3389/fimmu.2019.00717. eCollection 2019.

36.

Harnessing circulating microRNAs for early HIV diagnosis.

Vasan S, Robb ML.

EBioMedicine. 2019 Jun;44:18-19. doi: 10.1016/j.ebiom.2019.05.017. Epub 2019 May 13. No abstract available.

37.

Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression.

Pušnik J, Eller MA, Tassaneetrithep B, Schultz BT, Eller LA, Nitayaphan S, Kosgei J, Maganga L, Kibuuka H, Alter G, Michael NL, Robb ML, Streeck H.

J Virol. 2019 Jun 28;93(14). pii: e00377-19. doi: 10.1128/JVI.00377-19. Print 2019 Jul 15.

38.

Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort.

Trinh HV, Gohain N, Pham PT, Hamlin C, Song H, Sanders-Buell E, Bose M, Eller LA, Jain S, Uritskiy G, Rao VB, Tovanabutra S, Michael NL, Robb ML, Joyce MG, Rao M.

Cells. 2019 Apr 19;8(4). pii: E365. doi: 10.3390/cells8040365. Erratum in: Cells. 2019 Jun 06;8(6):. Jain, Swati [added]; Uritskiy, Gherman [added]; Rao, Venigalla B [added].

39.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
40.

Next-generation sequencing of HIV-1 single genome amplicons.

Kijak GH, Sanders-Buell E, Pham P, Harbolick EA, Oropeza C, O'Sullivan AM, Bose M, Beckett CG, Milazzo M, Robb ML, Peel SA, Scott PT, Michael NL, Armstrong AW, Kim JH, Brett-Major DM, Tovanabutra S.

Biomol Detect Quantif. 2019 Mar 11;17:100080. doi: 10.1016/j.bdq.2019.01.002. eCollection 2019 Mar.

41.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
42.

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA.

Immunity. 2019 Mar 19;50(3):677-691.e13. doi: 10.1016/j.immuni.2019.02.008. Epub 2019 Mar 12.

PMID:
30876875
43.

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer.

Ananthaswamy N, Fang Q, AlSalmi W, Jain S, Chen Z, Klose T, Sun Y, Liu Y, Mahalingam M, Chand S, Tovanabutra S, Robb ML, Rossmann MG, Rao VB.

Nat Commun. 2019 Feb 20;10(1):873. doi: 10.1038/s41467-019-08825-7.

44.

HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.

Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, Semwogerere M, Namagembe R, Nambuya A, Kafeero C, Tindikahwa A, Eller LA, Millard M, Gelderblom HC, Keshinro B, Adamu Y, Maswai J, Owuoth J, Sing'oei VC, Maganga L, Bahemana E, Khamadi S, Robb ML, Ake JA, Polyak CS, Kibuuka H.

PLoS One. 2019 Feb 5;14(2):e0211344. doi: 10.1371/journal.pone.0211344. eCollection 2019.

45.

Time to change the paradigm: limited condom and lubricant use among Nigerian men who have sex with men and transgender women despite availability and counseling.

Crowell TA, Baral SD, Schwartz S, Nowak RG, Kokogho A, Adebajo S, Keshinro B, Makanjuola O, Michael NL, Robb ML, Charurat ME, Ake JA; TRUST/RV368 Study Group.

Ann Epidemiol. 2019 Mar;31:11-19.e3. doi: 10.1016/j.annepidem.2018.12.004. Epub 2018 Dec 21.

PMID:
30642695
46.

Molecular epidemiology of a primarily MSM acute HIV-1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia.

Chang D, Sanders-Buell E, Bose M, O'Sullivan AM, Pham P, Kroon E, Colby DJ, Sirijatuphat R, Billings E, Pinyakorn S, Chomchey N, Rutvisuttinunt W, Kijak G, de Souza M, Excler JL, Phanuphak P, Phanuphak N, O'Connell RJ, Kim JH, Robb ML, Michael NL, Ananworanich J, Tovanabutra S; RV254/SEARCH 010 Study Group.

J Int AIDS Soc. 2018 Nov;21(11):e25204. doi: 10.1002/jia2.25204.

47.

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy.

Whitney JB, Lim SY, Osuna CE, Kublin JL, Chen E, Yoon G, Liu PT, Abbink P, Borducci EN, Hill A, Lewis MG, Geleziunas R, Robb ML, Michael NL, Barouch DH.

Nat Commun. 2018 Dec 21;9(1):5429. doi: 10.1038/s41467-018-07881-9.

48.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

49.

Noninfectious Comorbidity in the African Cohort Study.

Ake JA, Polyak CS, Crowell TA, Kiweewa F, Semwogerere M, Maganga L, Bahemana E, Maswai J, Langat R, Owuoth J, Otieno S, Keshinro B, Esber AL, Liu M, Eller LA, Ganesan K, Parikh AP, Hamm TE, Robb ML, Hickey PW, Valcour VG, Michael NL; African Cohort Study Team .

Clin Infect Dis. 2019 Aug 1;69(4):639-647. doi: 10.1093/cid/ciy981.

50.

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.

Pissani F, Schulte B, Eller MA, Schultz BT, Ratto-Kim S, Marovich M, Thongcharoen P, Sriplienchan S, Rerks-Ngarm S, Pitisuttithum P, Esser S, Alter G, Robb ML, Kim JH, Michael NL, Streeck H.

J Virol. 2018 Nov 12;92(23). pii: e01143-18. doi: 10.1128/JVI.01143-18. Print 2018 Dec 1.

Supplemental Content

Support Center